Accueil・Liste d'Actions・Eli Lilly and Co.

Eli Lilly and Co.

Fermé

SecteurSoins de santé

1,222 0.73

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1184.79

Max

1231.13

Chiffres clés
By Trading Economics
Revenu	758M 7.4B
Ventes	507M 20B
P/E Moyenne du Secteur	39.835 68.51
BPA	8.55
Rendement du dividende	0.54
Marge bénéficiaire	37.355
Employés	50,000
EBITDA	1.3B 9.7B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+16.03% upside

Dividendes
By Acuity
Rendement du dividende Moyenne du Secteur	0.54% 2.29%
Prochains Résultats	29 oct. 2026
Date du Prochain Dividende	10 sept. 2026
Date du Prochain Détachement de Dividende	14 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	249B 1T
Ouverture précédente	1221.27
Clôture précédente	1222

Eli Lilly and Co. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 août 2026, 23:16 UTC

News

Social Media

Eli Lilly and Co shares are lower in after-market hours, following a narrow trading range since Monday's close and reflecting broader market trends.

8 août 2026, 00:02 UTC

News

Eli Lilly shares are higher in after-market trading following FDA filing plans for retatrutide, a potential competitor in the weight-loss market.

7 août 2026, 19:16 UTC

News

Social Media

Eli Lilly shares are lower today, despite an increase in TRx sales to 34,219 from 29,388 last week. The stock remains within its one-month range.

6 août 2026, 19:16 UTC

Social Media

News

Eli Lilly shares rose as analysts raised price targets, reflecting strong quarterly results and demand growth for its obesity drugs.

5 août 2026, 23:42 UTC

News

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

4 août 2026, 23:02 UTC

Eli Lilly shares are higher in after-market trading, driven by a broader market rally and optimism surrounding potential oil supply agreements.

3 août 2026, 20:03 UTC

News

Social Media

Event

Eli Lilly's shares are declining amid negative sentiment despite expanding access to its obesity drug retatrutide and receiving FDA designation for olomorasib.

31 juil. 2026, 23:06 UTC

Eli Lilly and Co shares are higher in after-market trading, though they remain below their 20-day moving average by 2.91%. No specific news was identified.

30 juil. 2026, 21:01 UTC

Eli Lilly shares are higher in after-market trading, recovering from an earlier dip. Broader market sentiment remains positive amid geopolitical tensions and inflation concerns.

29 juil. 2026, 23:26 UTC

Eli Lilly and Co shares are lower in after-market hours amid unusual trading activity. Broader market volatility follows the Federal Reserve's interest rate decision.

28 juil. 2026, 22:06 UTC

Eli Lilly shares are lower in after-market hours, with no specific news identified. Broader market trends may be impacting sentiment following declines in the Nikkei 225 Index.

27 juil. 2026, 23:16 UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a decline since Monday's close amid a broader market downturn. No specific news was identified.

24 juil. 2026, 23:41 UTC

Eli Lilly and Co shares declined in after-market trading, experiencing notable fluctuations without any specific news to explain the price action.

23 juil. 2026, 10:06 UTC

Social Media

Eli Lilly shares are lower in pre-market trading, nearing the $1074–$1003 support zone. Broader market declines coincide with traders awaiting the ECB's interest rate decision.

22 juil. 2026, 23:16 UTC

Social Media

Eli Lilly acquires ATAI for $2.8 billion, entering the psychedelic medicine sector. Shares are higher in after-market trading following the announcement.

21 juil. 2026, 20:07 UTC

Social Media

News

Eli Lilly is higher today, supported by overall market strength and plans to defend against a lawsuit from Novo Nordisk over its weight-loss drugs.

20 juil. 2026, 23:16 UTC

Eli Lilly's shares are roughly flat in after-market trading, amid rising treasury yields and geopolitical tensions affecting interest-sensitive sectors like pharmaceuticals.

Comparaison

Variation de prix

Eli Lilly and Co. prévision

Objectif de Prix

By TipRanks

16.03% hausse

Prévisions sur 12 Mois

Moyen 1,375.78 USD 16.03%

Haut 1,600 USD

Bas 1,135 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

Achat

Maintien

Vente

Basé sur 20 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.